[S01HA03, tetracaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AX05, trazodone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Triamcinolone.]
[D07AC02, fluclorolone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluclorolone.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Acetylsalicylic acid.]
[H02AB11, prednylidene, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednylidene.]
[C01CA18, octopamine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aldosterone.]
[R02AD01, benzocaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N04AC01, benztropine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Benzatropine.]
[P03AX06, benzyl alcohol, Hyaluronidase (human recombinant) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03BA03, betamethasone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Bethanidine.]
[N06AX11, mirtazapine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Mirtazapine.]
[N02BA02, aloxiprin, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aloxiprin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Brompheniramine.]
[N01BB01, bupivacaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX07, azelastine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Azelastine.]
[S01HA02, benoxinate, Hyaluronidase (human recombinant) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA15, butriptyline, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Butriptyline.]
[S01GX12, cetirizine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Chloroprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AC03, chloropyramine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorphenoxamine.]
[H02AB14, cloprednol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cloprednol.]
[H02AB17, cortivazol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cortivazol.]
[D07XB03, fluprednidene, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluprednidene.]
[R02AD04, dyclonine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorotrianisene.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorpromazine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase (human recombinant).]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluocinolone acetonide.]
[A02BA01, cimetidine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cimetidine.]
[R06AA04, clemastine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Clemastine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Clonidine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[S01GX06, emedastine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Emedastine.]
[H02AB15, meprednisone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methdilazine.]
[R06AE03, cyclizine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Cyclizine.]
[C01CA05, norfenefrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Norfenefrine.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dexamethasone.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[R06AX04, phenindamine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Phenindamine.]
[R02AA19, phenol, Hyaluronidase (human recombinant) can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02DA04, dibucaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Diethylstilbestrol.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Polyestradiol phosphate.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimetindene.]
[S01HA04, proparacaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AA02, diphenhydramine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX08, risperidone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Risperidone.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Dopamine.]
[H01AA01, corticotropin, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Corticotropin.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Tetryzoline.]
[G03CX01, tibolone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Tibolone.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[H02CA01, trilostane, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Trilostane.]
[R06AX21, tritoqualine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Tritoqualine.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Epinastine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Epinephrine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Ergometrine.]
[G03CA03, estradiol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Conjugated estrogens.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Ethinylestradiol.]
[M01AC06, meloxicam, Hyaluronidase (human recombinant) can cause an increase in the absorption of Meloxicam resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Etilefrine.]
[N01BB07, etidocaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Etomidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Famotidine.]
[S01CB05, fluorometholone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluorometholone.]
[N06BX17, adrafinil, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Adrafinil.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase (human recombinant).]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Dexmedetomidine.]
[N02CX05, fonazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Dimetotiazine.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hydrocortisone.]
[N05BB01, hydroxyzine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Hydroxyzine.]
[N06AA02, imipramine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Imipramine.]
[N01BB08, articaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH03, olanzapine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Olanzapine.]
[S02DA01, lidocaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[N06AA21, maprotiline, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Maprotiline.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Mephentermine.]
[N01BB03, mepivacaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Metaraminol.]
[A03AB07, methantheline, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methapyrilene.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Methoxamine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Methyldopa.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Methylprednisolone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase (human recombinant).]
[N06AA09, amitriptyline, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Amitriptyline.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase (human recombinant).]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Norepinephrine.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Oxymetazoline.]
[H02AB05, paramethasone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Paramethasone.]
[R06AB05, pheniramine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Phenylephrine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase (human recombinant).]
[S03BA02, prednisolone, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Prednisolone.]
[R06AX05, antazoline, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Antazoline.]
[N01BB04, prilocaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01HA05, procaine, Hyaluronidase (human recombinant) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AA03, promazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Promethazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Propiomazine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Aripiprazole.]
[A02BA02, ranitidine, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Ranitidine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Salicylic acid.]
[S01HA03, tetracaine, Hyaluronidase can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AX05, trazodone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.]
[D07AC02, fluclorolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluclorolone.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.]
[H02AB11, prednylidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednylidene.]
[C01CA18, octopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.]
[R02AD01, benzocaine, Hyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N04AC01, benztropine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.]
[P03AX06, benzyl alcohol, Hyaluronidase can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03BA03, betamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bethanidine.]
[N06AX11, mirtazapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.]
[N02BA02, aloxiprin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aloxiprin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.]
[N01BB01, bupivacaine, Hyaluronidase can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX07, azelastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.]
[S01HA02, benoxinate, Hyaluronidase can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA15, butriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butriptyline.]
[S01GX12, cetirizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, Hyaluronidase can cause an increase in the absorption of Chloroprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AC03, chloropyramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.]
[H02AB14, cloprednol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cloprednol.]
[H02AB17, cortivazol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortivazol.]
[D07XB03, fluprednidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.]
[R02AD04, dyclonine, Hyaluronidase can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be decreased when used in combination with Hyaluronidase.]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpromazine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone acetonide.]
[A02BA01, cimetidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.]
[R06AA04, clemastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Clonidine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase.]
[S01GX06, emedastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Emedastine.]
[H02AB15, meprednisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methdilazine.]
[R06AE03, cyclizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.]
[C01CA05, norfenefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norfenefrine.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase.]
[R06AX04, phenindamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenindamine.]
[R02AA19, phenol, Hyaluronidase can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02DA04, dibucaine, Hyaluronidase can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene.]
[S01HA04, proparacaine, Hyaluronidase can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AA02, diphenhydramine, Hyaluronidase can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX08, risperidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Risperidone.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.]
[H01AA01, corticotropin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Corticotropin.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetryzoline.]
[G03CX01, tibolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tibolone.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase.]
[H02CA01, trilostane, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trilostane.]
[R06AX21, tritoqualine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tritoqualine.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Epinephrine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ergometrine.]
[G03CA03, estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated estrogens.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinylestradiol.]
[M01AC06, meloxicam, Hyaluronidase can cause an increase in the absorption of Meloxicam resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etilefrine.]
[N01BB07, etidocaine, Hyaluronidase can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etomidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.]
[S01CB05, fluorometholone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.]
[N06BX17, adrafinil, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Adrafinil.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dexmedetomidine.]
[N02CX05, fonazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetotiazine.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.]
[N05BB01, hydroxyzine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.]
[N06AA02, imipramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.]
[N01BB08, articaine, Hyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH03, olanzapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olanzapine.]
[S02DA01, lidocaine, Hyaluronidase can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.]
[N06AA21, maprotiline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mephentermine.]
[N01BB03, mepivacaine, Hyaluronidase can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Metaraminol.]
[A03AB07, methantheline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methoxamine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methyldopa.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.]
[N06AA09, amitriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amitriptyline.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norepinephrine.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxymetazoline.]
[H02AB05, paramethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.]
[R06AB05, pheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Phenylephrine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase.]
[S03BA02, prednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.]
[R06AX05, antazoline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.]
[N01BB04, prilocaine, Hyaluronidase can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01HA05, procaine, Hyaluronidase can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AA03, promazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Propiomazine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.]
[A02BA02, ranitidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.]
[S01HA03, tetracaine, Hyaluronidase can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AX05, trazodone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.]
[D07AC02, fluclorolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluclorolone.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.]
[H02AB11, prednylidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednylidene.]
[C01CA18, octopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.]
[R02AD01, benzocaine, Hyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N04AC01, benztropine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.]
[P03AX06, benzyl alcohol, Hyaluronidase can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03BA03, betamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bethanidine.]
[N06AX11, mirtazapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.]
[N02BA02, aloxiprin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aloxiprin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.]
[N01BB01, bupivacaine, Hyaluronidase can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX07, azelastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.]
[S01HA02, benoxinate, Hyaluronidase can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA15, butriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butriptyline.]
[S01GX12, cetirizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, Hyaluronidase can cause an increase in the absorption of Chloroprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AC03, chloropyramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.]
[H02AB14, cloprednol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cloprednol.]
[H02AB17, cortivazol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortivazol.]
[D07XB03, fluprednidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.]
[R02AD04, dyclonine, Hyaluronidase can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be decreased when used in combination with Hyaluronidase.]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpromazine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone acetonide.]
[A02BA01, cimetidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.]
[R06AA04, clemastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Clonidine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase.]
[S01GX06, emedastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Emedastine.]
[H02AB15, meprednisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methdilazine.]
[R06AE03, cyclizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.]
[C01CA05, norfenefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norfenefrine.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase.]
[R06AX04, phenindamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenindamine.]
[R02AA19, phenol, Hyaluronidase can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02DA04, dibucaine, Hyaluronidase can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene.]
[S01HA04, proparacaine, Hyaluronidase can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AA02, diphenhydramine, Hyaluronidase can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX08, risperidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Risperidone.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.]
[H01AA01, corticotropin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Corticotropin.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetryzoline.]
[G03CX01, tibolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tibolone.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase.]
[H02CA01, trilostane, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trilostane.]
[R06AX21, tritoqualine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tritoqualine.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Epinephrine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ergometrine.]
[G03CA03, estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated estrogens.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinylestradiol.]
[M01AC06, meloxicam, Hyaluronidase can cause an increase in the absorption of Meloxicam resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etilefrine.]
[N01BB07, etidocaine, Hyaluronidase can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etomidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.]
[S01CB05, fluorometholone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.]
[N06BX17, adrafinil, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Adrafinil.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dexmedetomidine.]
[N02CX05, fonazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetotiazine.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.]
[N05BB01, hydroxyzine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.]
[N06AA02, imipramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.]
[N01BB08, articaine, Hyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH03, olanzapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olanzapine.]
[S02DA01, lidocaine, Hyaluronidase can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.]
[N06AA21, maprotiline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mephentermine.]
[N01BB03, mepivacaine, Hyaluronidase can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Metaraminol.]
[A03AB07, methantheline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methoxamine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methyldopa.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.]
[N06AA09, amitriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amitriptyline.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norepinephrine.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxymetazoline.]
[H02AB05, paramethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.]
[R06AB05, pheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Phenylephrine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase.]
[S03BA02, prednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.]
[R06AX05, antazoline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.]
[N01BB04, prilocaine, Hyaluronidase can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01HA05, procaine, Hyaluronidase can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AA03, promazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Propiomazine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.]
[A02BA02, ranitidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.]
[S01HA03, tetracaine, Hyaluronidase (ovine) can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AX05, trazodone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Triamcinolone.]
[D07AC02, fluclorolone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluclorolone.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Acetylsalicylic acid.]
[H02AB11, prednylidene, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednylidene.]
[C01CA18, octopamine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aldosterone.]
[R02AD01, benzocaine, Hyaluronidase (ovine) can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N04AC01, benztropine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Benzatropine.]
[P03AX06, benzyl alcohol, Hyaluronidase (ovine) can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03BA03, betamethasone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Bethanidine.]
[N06AX11, mirtazapine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mirtazapine.]
[N02BA02, aloxiprin, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aloxiprin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Brompheniramine.]
[N01BB01, bupivacaine, Hyaluronidase (ovine) can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX07, azelastine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Azelastine.]
[S01HA02, benoxinate, Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA15, butriptyline, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Butriptyline.]
[S01GX12, cetirizine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, Hyaluronidase (ovine) can cause an increase in the absorption of Chloroprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AC03, chloropyramine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorphenoxamine.]
[H02AB14, cloprednol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cloprednol.]
[H02AB17, cortivazol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cortivazol.]
[D07XB03, fluprednidene, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene.]
[R02AD04, dyclonine, Hyaluronidase (ovine) can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be decreased when used in combination with Hyaluronidase (ovine).]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorotrianisene.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorpromazine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase (ovine).]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluocinolone acetonide.]
[A02BA01, cimetidine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cimetidine.]
[R06AA04, clemastine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Clemastine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase (ovine).]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Clonidine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase (ovine).]
[S01GX06, emedastine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Emedastine.]
[H02AB15, meprednisone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methdilazine.]
[R06AE03, cyclizine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Cyclizine.]
[C01CA05, norfenefrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norfenefrine.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dexamethasone.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase (ovine).]
[R06AX04, phenindamine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Phenindamine.]
[R02AA19, phenol, Hyaluronidase (ovine) can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02DA04, dibucaine, Hyaluronidase (ovine) can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Diethylstilbestrol.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Polyestradiol phosphate.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetindene.]
[S01HA04, proparacaine, Hyaluronidase (ovine) can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AA02, diphenhydramine, Hyaluronidase (ovine) can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX08, risperidone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Risperidone.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dopamine.]
[H01AA01, corticotropin, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Corticotropin.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Tetryzoline.]
[G03CX01, tibolone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tibolone.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase (ovine).]
[H02CA01, trilostane, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Trilostane.]
[R06AX21, tritoqualine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Tritoqualine.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Epinastine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Epinephrine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Ergometrine.]
[G03CA03, estradiol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Conjugated estrogens.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ethinylestradiol.]
[M01AC06, meloxicam, Hyaluronidase (ovine) can cause an increase in the absorption of Meloxicam resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etilefrine.]
[N01BB07, etidocaine, Hyaluronidase (ovine) can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Etomidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Famotidine.]
[S01CB05, fluorometholone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluorometholone.]
[N06BX17, adrafinil, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Adrafinil.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase (ovine).]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dexmedetomidine.]
[N02CX05, fonazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Dimetotiazine.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydrocortisone.]
[N05BB01, hydroxyzine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Hydroxyzine.]
[N06AA02, imipramine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Imipramine.]
[N01BB08, articaine, Hyaluronidase (ovine) can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH03, olanzapine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Olanzapine.]
[S02DA01, lidocaine, Hyaluronidase (ovine) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase (ovine).]
[N06AA21, maprotiline, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Maprotiline.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Mephentermine.]
[N01BB03, mepivacaine, Hyaluronidase (ovine) can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Metaraminol.]
[A03AB07, methantheline, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methapyrilene.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methoxamine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Methyldopa.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Methylprednisolone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase (ovine).]
[N06AA09, amitriptyline, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Amitriptyline.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase (ovine).]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Norepinephrine.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Oxymetazoline.]
[H02AB05, paramethasone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Paramethasone.]
[R06AB05, pheniramine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Phenylephrine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase (ovine).]
[S03BA02, prednisolone, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Prednisolone.]
[R06AX05, antazoline, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Antazoline.]
[N01BB04, prilocaine, Hyaluronidase (ovine) can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01HA05, procaine, Hyaluronidase (ovine) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AA03, promazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Promethazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Propiomazine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.]
[A02BA02, ranitidine, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Ranitidine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Salicylic acid.]
[S01HA03, tetracaine, Hyaluronidase can cause an increase in the absorption of Tetracaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AX05, trazodone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.]
[D07AC02, fluclorolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluclorolone.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zuclopenthixol.]
[N05AE04, ziprasidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ziprasidone.]
[N02BA01, aspirin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.]
[H02AB11, prednylidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednylidene.]
[C01CA18, octopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Octopamine.]
[H02AA01, aldosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.]
[R02AD01, benzocaine, Hyaluronidase can cause an increase in the absorption of Benzocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N04AC01, benztropine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.]
[P03AX06, benzyl alcohol, Hyaluronidase can cause an increase in the absorption of Benzyl alcohol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S03BA03, betamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bethanidine.]
[N06AX11, mirtazapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.]
[N02BA02, aloxiprin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aloxiprin.]
[R06AB01, brompheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.]
[N01BB01, bupivacaine, Hyaluronidase can cause an increase in the absorption of Bupivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01GX07, azelastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.]
[S01HA02, benoxinate, Hyaluronidase can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA15, butriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butriptyline.]
[S01GX12, cetirizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.]
[N01BA04, chloroprocaine, Hyaluronidase can cause an increase in the absorption of Chloroprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AC03, chloropyramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chloropyramine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.]
[H02AB14, cloprednol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cloprednol.]
[H02AB17, cortivazol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortivazol.]
[D07XB03, fluprednidene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.]
[R02AD04, dyclonine, Hyaluronidase can cause an increase in the absorption of Dyclonine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD14, remimazolam, The therapeutic efficacy of Remimazolam can be decreased when used in combination with Hyaluronidase.]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene.]
[R06AB04, chlorpheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorpromazine.]
[N05BA18, ethyl loflazepate, The therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Hyaluronidase.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone acetonide.]
[A02BA01, cimetidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.]
[R06AA04, clemastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase.]
[S01EA04, clonidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Clonidine.]
[N05BA13, halazepam, The therapeutic efficacy of Halazepam can be decreased when used in combination with Hyaluronidase.]
[S01GX06, emedastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Emedastine.]
[H02AB15, meprednisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mequitazine.]
[R06AD04, methdilazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methdilazine.]
[R06AE03, cyclizine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.]
[C01CA05, norfenefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norfenefrine.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycortone.]
[S03BA01, dexamethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase.]
[R06AX04, phenindamine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenindamine.]
[R02AA19, phenol, Hyaluronidase can cause an increase in the absorption of Phenol resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S02DA04, dibucaine, Hyaluronidase can cause an increase in the absorption of Cinchocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.]
[R06AA11, dimenhydrinate, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene.]
[S01HA04, proparacaine, Hyaluronidase can cause an increase in the absorption of Proparacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R06AA02, diphenhydramine, Hyaluronidase can cause an increase in the absorption of Diphenhydramine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AX08, risperidone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Risperidone.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.]
[H01AA01, corticotropin, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Corticotropin.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetryzoline.]
[G03CX01, tibolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tibolone.]
[N05CD11, triazulenone, The therapeutic efficacy of Loprazolam can be decreased when used in combination with Hyaluronidase.]
[H02CA01, trilostane, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trilostane.]
[R06AX21, tritoqualine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tritoqualine.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Epinephrine.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ergometrine.]
[G03CA03, estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated estrogens.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinylestradiol.]
[M01AC06, meloxicam, Hyaluronidase can cause an increase in the absorption of Meloxicam resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etilefrine.]
[N01BB07, etidocaine, Hyaluronidase can cause an increase in the absorption of Etidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etomidate.]
[A02BA04, nizatidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.]
[A02BA03, famotidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.]
[S01CB05, fluorometholone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.]
[N06BX17, adrafinil, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Adrafinil.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dexmedetomidine.]
[N02CX05, fonazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetotiazine.]
[N01BB08, articaine, Hyaluronidase can cause an increase in the absorption of Articaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AH03, olanzapine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olanzapine.]
[S02DA01, lidocaine, Hyaluronidase can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.]
[N06AA21, maprotiline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mephentermine.]
[N01BB03, mepivacaine, Hyaluronidase can cause an increase in the absorption of Mepivacaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Metaraminol.]
[A03AB07, methantheline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methantheline.]
[R06AC05, methapyrilene, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methoxamine.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Methyldopa.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.]
[N05CD08, midazolam, The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.]
[N06AA09, amitriptyline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amitriptyline.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Norepinephrine.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxymetazoline.]
[H02AB05, paramethasone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.]
[R06AB05, pheniramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Phenylephrine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase.]
[S03BA02, prednisolone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.]
[R06AX05, antazoline, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.]
[N01BB04, prilocaine, Hyaluronidase can cause an increase in the absorption of Prilocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01HA05, procaine, Hyaluronidase can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05AA03, promazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Propiomazine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aripiprazole.]
[A02BA02, ranitidine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.]
[N05BB01, hydroxyzine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.]
[N06AA02, imipramine, The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Imipramine.]
